Mechanism of immune suppression by allogeneic blood transfusion in patients with gastrointestinal cancer.
Project/Area Number |
06671303
|
Research Category |
Grant-in-Aid for General Scientific Research (C)
|
Allocation Type | Single-year Grants |
Research Field |
Digestive surgery
|
Research Institution | Saitama Medical School |
Principal Investigator |
TOHYAMA Hiroshi Saitama Medical School, Faculty of Medicine, Professor, 医学部, 教授 (00008278)
|
Co-Investigator(Kenkyū-buntansha) |
SHISHIKURA Yuko Saitama Medical School, Faculty of Medicine, Assistant, 医学部, 助手 (80181105)
MURATA Nobuo Saitama Medical School, Faculty of Medicine, Ass, Prof., 医学部, 助教授 (10200297)
MAEDA Hiroo Saitama Medical School, Faculty of Medicine, Professor, 医学部, 教授 (30134597)
|
Project Period (FY) |
1994 – 1995
|
Project Status |
Completed (Fiscal Year 1995)
|
Budget Amount *help |
¥400,000 (Direct Cost: ¥400,000)
Fiscal Year 1995: ¥400,000 (Direct Cost: ¥400,000)
|
Keywords | allogeneic blood transfusion / Gastrointestinal cancer / Immune suppression / Survival rate |
Research Abstract |
Whether allogeneic blood transfusion gives rise to adverse effect on survival or postoperational infection in patients who received allogeneic blood as compared with those who did not received is controversial. We studied retrospetively survival rate in patients who underwent radical operation for gastrointestinal cancer : 18 allogeneic blood, 33 autologous blood, and 70 no blood transfusion (66 gastric cancer, 29 colon cancer, and 26 rectal cancer), a total of 121 cancer patients were analyzed. We compared 3-year survival rate of the three patient groups ; 86.3% in autologous transfusion group was comparable with 88.1% of no transfusion group but higher, although not significantly, than 76.6% in allogeneic transfusion group. We also analyzed the change of immunological markers, natural killer cell activities and lymphocyte subsets in 8 patients undergoing radical operation. However, we could not find any significant differences among before nad after operation, and among the groups of allogeneic, autologous, and no transfusion. In conclusion, the effects of blood transfusion on survival and immunological markers of the patients with cancer were not demonstrated. A large-scale multi-center study is warranted.
|
Report
(3 results)
Research Products
(17 results)